SwedenBIO and QuintilesIMS jointly invites to Breakfast Meeting on Rare Disease

The QuintilesIMS Institute will shortly publish a very comprehensive study of the rare disease market in US. We will have the privilege to have the author, Murray Aitkens, SVP & Exec Dir, QI Institute, give a briefing of the learnings from the study.

In addition, an update of the drivers of the Swedish drug budget, including to what extent orphan drugs impact the overall budget, will be given by Per Troein, VP Supplier & Assoc Relations, responsible for the underlying analysis completed for Socialstyrelsen’s autumn update to the Government.


8.00 – 8.30 Breakfast is served

8.30 – 8.40 SwedenBIO welcomes and presents the Swedish Drug Discovery & Development Pipeline Report 2016 – Björn Ursing

08.40 – 9.10 Rare disease market in the US – Murray Aitken

9.10 – 9.30 Orphan drugs budget impact in Sweden – Per Troein

9.30 – 10.00 Open time for questions